Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device ...
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...
UBS raised the firm’s price target on Abbott (ABT) to $148 from $146 and keeps a Buy rating on the shares. Abbott’s quarterly results ...
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Abbott Laboratories posted lower-than-expected sales in its latest quarter despite growth across most of its segments, though shares rose as the company forecast strong earnings growth for 2025. The ...